InvestorsHub Logo
Followers 45
Posts 5645
Boards Moderated 0
Alias Born 04/05/2015

Re: jondoeuk post# 232946

Wednesday, 06/12/2019 1:21:24 PM

Wednesday, June 12, 2019 1:21:24 PM

Post# of 721596

As for the third the company tested its EDGE platform against public methods and looked at how both compared to the tandem minigene approach used by Dr. Rosenberg/NCI [3]. In the top 20: The majority (19/26, 73%) of neoantigens would be included with EDGE vs. only 9/26 (35%) with public tools. They will try to prioritise clonal over subclonal neoantigens [4].



Oh dear, no wonder they will fail.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News